Indivior (NASDAQ:INDV) Issues Quarterly Earnings Results, Beats Estimates By $0.26 EPS

Key Points

• Indivior beat quarterly expectations: The company reported EPS of $1.32, exceeding the $1.06 consensus by $0.26, while revenue reached $356.0 million versus estimates of $329.35 million.
• Shares rose to $35.25 during Thursday trading, while the company announced a special $8.13-per-share dividend for shareholders of record on October 30.
• Analysts remain generally positive, with an average “Buy” rating and a consensus price target of $45.50; recent actions included Barclays raising its target to $45 and Zacks upgrading the stock to “strong buy.”

Indivior (NASDAQ:INDV - Get Free Report) issued its quarterly earnings data on Thursday. The company reported $1.32 EPS for the quarter, topping analysts' consensus estimates of $1.06 by $0.26, FiscalAI reports. The firm had revenue of $356.00 million for the quarter, compared to analyst estimates of $329.35 million. Indivior had a net margin of 26.65% and a negative return on equity of 283.11%.

Indivior Stock Performance

Shares of NASDAQ:INDV traded up $0.48 during midday trading on Thursday, reaching $35.25. The company's stock had a trading volume of 4,934,641 shares, compared to its average volume of 2,221,596. The firm has a market capitalization of $4.16 billion, a price-to-earnings ratio of 12.63 and a beta of 0.87. The firm has a 50 day moving average price of $35.32 and a two-hundred day moving average price of $35.62. Indivior has a fifty-two week low of $27.68 and a fifty-two week high of $42.81.

Indivior Announces Dividend

The company also recently announced a special dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 30th will be issued a $8.13 dividend.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Craig Hallum reissued a "buy" rating and issued a $53.00 target price on shares of Indivior in a research note on Tuesday, August 4th. Zacks Research raised shares of Indivior from a "hold" rating to a "strong-buy" rating in a research note on Friday, October 2nd. Barclays lifted their price objective on shares of Indivior from $43.00 to $45.00 and gave the company an "overweight" rating in a report on Wednesday. Finally, Weiss Ratings cut shares of Indivior from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday, September 24th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $45.50.

Insiders Place Their Bets

In related news, CAO Woodrow D. Anderson acquired 1,500 shares of the stock in a transaction dated Thursday, August 27th. The stock was purchased at an average cost of $35.69 per share, with a total value of $53,535.00. Following the completion of the purchase, the chief accounting officer directly owned 27,638 shares in the company, valued at $986,400.22. This trade represents a 5.74% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.74% of the company's stock.

About Indivior

Indivior PLC NASDAQ: INDV is a global pharmaceutical company focused on developing and commercializing medicines for substance use disorders and serious mental health conditions. Its portfolio is centered on treatments for opioid use disorder, opioid overdose, and related medical needs.

The company's principal products include Sublocade, an extended-release buprenorphine injection for opioid use disorder; Suboxone, a buprenorphine and naloxone treatment available in film and other formulations; and Opvee, a nalmefene nasal spray intended for the emergency treatment of known or suspected opioid overdose.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.